about
The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease miceLatrepirdine for Alzheimer's diseaseDimebon for Alzheimer's diseaseProtein homeostasis as a therapeutic target for diseases of protein conformationEarly Signs of Pathological Cognitive Aging in Mice Lacking High-Affinity Nicotinic Receptors.Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's diseaseAn aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's diseasePackages of care for dementia in low- and middle-income countries.Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's diseaseQuantitative structural MRI for early detection of Alzheimer's disease.Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors.Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors.A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (Aβ) production.Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.Fumanjian, a Classic Chinese Herbal Formula, Can Ameliorate the Impairment of Spatial Learning and Memory through Apoptotic Signaling Pathway in the Hippocampus of Rats with Aβ 1-40 -Induced Alzheimer's Disease.Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis.Versatile somatic gene transfer for modeling neurodegenerative diseases.Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetesTargeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.Functional neural correlates of attentional deficits in amnestic mild cognitive impairment.Report of the task force on designing clinical trials in early (predementia) AD.Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models.Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathyCarnosine's effect on amyloid fibril formation and induced cytotoxicity of lysozyme.Age, Alzheimer's disease, and the big picture.Design of Peptide Substrate for Sensitively and Specifically Detecting Two Aβ-Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme.A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trialVascular disease and dementias: paradigm shifts to drive research in new directionsAD vaccines: conclusions and future directions.Neurodegenerative disorders and nanoformulated drug development.Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Murine models of Alzheimer's disease and their use in developing immunotherapies.Perispinal etanercept: a new therapeutic paradigm in neurology.The role of tau in Alzheimer's disease and related disorders.
P2860
Q21195685-9E078877-D3D7-4216-8852-0B6673CD4EAAQ24186444-3C9AFB3F-A632-4D3D-B9A4-658AF0C0EE2CQ24234998-624C9C2D-AC95-4D2B-B1B7-1C34066EDE14Q27003283-5624F1A1-8D2B-4D07-B0D9-66A20AD7127AQ27323221-B460D90C-AAC2-4EF3-80EA-FF7AAD04B538Q28481384-726A5E82-8F4C-4A05-A7FA-2EB5F4943D24Q28581962-16802247-9303-4FB6-A2CD-C546BD9CC572Q33514859-A36D4F80-5833-4B19-98F1-6CACCBF87CD1Q33591314-C860AE50-4796-432C-9A8F-790D51BB92C9Q33729033-F8EDD03F-A5F6-44C2-9ED6-82E061F6F8D4Q33736582-CE6243D6-65F6-42DA-A61D-91DDF45E74DAQ33774384-164ECCD5-35D5-45F0-A752-BD207F71ADF4Q33787562-F460ED10-9C3C-4739-B748-2F5A433DC0ACQ33833703-B623333B-2639-4333-8A99-F43304343BA9Q33842520-2DEFBCB6-0A47-4384-8079-EF97A5F41737Q33876308-CA4E7825-E217-4F28-8EB3-F16CF9FB153FQ34176310-EC33AF6C-49C8-43D8-8295-04B7B5F7A20AQ34285870-9AF07109-DA34-4C55-96ED-E38F8FBB57A0Q34299928-5B57E846-CE98-4E92-BABC-8C384954FD44Q34407220-7FE5ED7D-7279-449F-A8F0-0073BB5A7465Q34552095-480D90D2-0F5D-4300-8243-07678319BDDEQ34555301-8CA74A95-EC2A-4F71-A54E-AA40BE12C41EQ34725521-72705DB9-DD28-403F-8EC7-DF3204D2B6A5Q34811570-16607E05-B8BF-4AF5-87FC-6D3F88FCC3E7Q34973787-53FBA9CC-F4DE-4DD9-8EF5-7076E220A0CEQ35069891-63ADE33E-EC38-491A-A8BA-D42D9CB57FB9Q35660351-A1CD51B9-2C4E-48A9-99BD-82D5EE564661Q35994771-E4A59BF2-6085-4899-AC16-A669C8E3C9A2Q36562466-3EDE31B5-CF5B-4FC4-B447-BD57FCE5B62AQ36771721-45ABEDBD-24AF-456B-AB0B-A4A1BA3068F9Q36790089-7D4457BE-09BA-4980-B6BB-536BFB429CE7Q36808201-0782EF6E-0187-4D4C-941F-673B42F6DE9CQ37438273-9F197E01-95FB-4E07-834F-1B422AFFE23BQ37538771-796543CE-0B92-4DE0-A803-60CDE3848045Q37600876-84AD69F4-2AD2-4A0E-94F3-0E95738BD98EQ37655247-B41BC69B-C7F3-4936-B537-341991C88EFBQ37681432-E3A32445-FA51-47CF-B47E-838C43FF01CCQ37752915-0B5C561A-DACA-426C-9342-E8119F1B5DB6Q37762260-0E77AD55-5CE8-492B-8DAF-BD1E4E48AC43Q37765632-B548D54C-1A49-4B7F-B556-65AD9E07F38E
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Recent developments in Alzheimer's disease therapeutics
@ast
Recent developments in Alzheimer's disease therapeutics
@en
Recent developments in Alzheimer's disease therapeutics
@en-gb
Recent developments in Alzheimer's disease therapeutics
@nl
type
label
Recent developments in Alzheimer's disease therapeutics
@ast
Recent developments in Alzheimer's disease therapeutics
@en
Recent developments in Alzheimer's disease therapeutics
@en-gb
Recent developments in Alzheimer's disease therapeutics
@nl
prefLabel
Recent developments in Alzheimer's disease therapeutics
@ast
Recent developments in Alzheimer's disease therapeutics
@en
Recent developments in Alzheimer's disease therapeutics
@en-gb
Recent developments in Alzheimer's disease therapeutics
@nl
P2860
P3181
P356
P1433
P1476
Recent developments in Alzheimer's disease therapeutics
@en
P2093
Michael S Rafii
P2860
P2888
P3181
P356
10.1186/1741-7015-7-7
P407
P5008
P577
2009-02-19T00:00:00Z
P5875
P6179
1032108299